This study uses single-cell transcriptomics on patient-derived organoids to identify AGRIN as a regulator of metastatic competence in high-grade serous ovarian cancer.

bioRxiv · Jun 9, 2026 · PreprintCancer Biology

Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2-deficient ovarian cancer model

Yukihide Ota, Vijayalaxmi G. Gupta, Bisiayo Fashemi, Moreniola Akande, Elizabeth Babu, Prasanth Thuthika, Maia Lina Elizagaray, Lulu Sun, Brooke E. Sanders, Lindsay M. Kuroki, Carolyn Kay McCourt, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, David Gardner Mutch, , Dineo Khabele

This study identifies RAD52 as a target to overcome PARP inhibitor resistance in BRCA2-deficient ovarian cancer by showing its role in DNA repair and demonstrating synergistic effects with PARP inhibitors.

bioRxiv · Sep 24, 2025 · PreprintCancer Biology

Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms

Elena Lomonosova, Megan Loeb, Kevin Rodriguez, Lilian N. van Biljon, Joshua D. Brill, Angela M. Schab, Margaret Minett, Jaeden Barron, Maya Bittner, Jiyoung Park, Rebecca Drexler, Carmen Sandoval, Alyssa Oplt, Eden Gallup, Prasanth Thuthika, , Mary Margaret Mullen

The paper identifies COPS5 as a therapeutic target for overcoming platinum resistance in ovarian cancer by inhibiting nucleotide excision repair and interstrand crosslink repair.

bioRxiv · Aug 4, 2025 · PreprintCancer Biology

Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer

Angela M. Schab, Amanda J. Compadre, Rikki Drexler, Megan Loeb, Kevin Rodriguez, Joshua D. Brill, Shariska Petersen Harrington, Carmen Sandoval, Brooke E. Sanders, Lindsay M. Kuroki, Carolyn Kay McCourt, Andrea R. Hagemann, Premal H. Thaker, David Gardner Mutch, Matthew A. Powell, , Mary Margaret Mullen

This study identifies phospho-RPA2 as a biomarker predicting response to platinum and PARP inhibitors in HR-proficient ovarian cancer, showing higher pathologic complete response and longer survival in pRPA2-High tumors.

Journal of Clinical Investigation · May 20, 2025Peer-reviewedCancer Biology